Cancer-related Venous Thromboembolic Disease - Cohort Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorUniversity Hospital, Brest

About this trial

Venous thromboembolic disease (VTE) is a common (1/1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)). In cancer patients, the risk of developing VTE is high and constitutes a negative prognostic factor for cancer; the risk of bleeding is also increased. The study of VTE in the context of cancer is a major challenge, given the frequency of the association, the heterogeneity of the situations, the risk factors involved and the therapeutic issues in both curative and primary prevention; in this field, many uncertainties remain, justifying a study focused on the association of VTE and cancer.

Eligibility criteria

Qualifiers

Patients aged 18 years and more.

Patients with active cancer or requiring cancer treatment at the time of their VTE episode

Patients with documented VTE less than 2 years old

Patients affiliated to the social security system

Disqualifiers

Patient under 18

Refusal to participate

Incapacity to consent to the study

Patient under guardianship

Trial design

Treatments tested in this trial

  • Collection of biological samples

Treatment groups

150 Participants
are divided into 1 treatment group

Sponsors and collaborators